Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Frontiers in Microbiomes
|
March 19, 2026
Live biotherapeutic products: a capstone for prevention of recurrent <i>Clostridiodes difficile</i> infection
Kanika Sehgal, Paul Feuerstadt
Expert Review of Gastroenterology & Hepatology
|
July 30, 2021
Gut microbiota: a target for intervention in obesity
Kanika Sehgal, Sahil Khanna
Therapeutic Advances in Gastroenterology
|
March 22, 2021
Gut microbiome and <i>Clostridioides difficile</i> infection: a closer look at the microscopic interface
Kanika Sehgal, Sahil Khanna
Therapeutic Advances in Gastroenterology
|
May 17, 2021
Immune response against <i>Clostridioides difficile</i> and translation to therapy
Kanika Sehgal, Sahil Khanna
Intestinal Research
|
November 29, 2020
Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Translational Gastroenterology and Hepatology
|
November 29, 2023
The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent <i>Clostridiodes difficile</i>
Kanika Sehgal, Paul Feuerstadt
Alimentary Pharmacology & Therapeutics
|
September 2, 2024
Editorial: Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low-dose rivaroxaban or the combination: Secondary analysis of the COMPASS randomised controlled trial
Kanika Sehgal, Dennis L Shung
Therapeutic Advances in Gastroenterology
|
June 9, 2021
The interplay of <i>Clostridioides difficile</i> infection and inflammatory bowel disease
Kanika Sehgal, Devvrat Yadav, Sahil Khanna
JAMA
|
August 8, 2022
Treatment of Clostridioides difficile Infection
Kanika Sehgal, Adam S Cifu, Sahil Khanna
Infectious Disease Clinics of North America
|
August 12, 2025
Making Sense of Differing Guidelines for Clostridioides difficile Infection
Kanika Sehgal, Paul Feuerstadt, Mark H Wilcox
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Frontiers in Microbiomes
|
March 19, 2026
Live biotherapeutic products: a capstone for prevention of recurrent <i>Clostridiodes difficile</i> infection
Kanika Sehgal, Paul Feuerstadt
Expert Review of Gastroenterology & Hepatology
|
July 30, 2021
Gut microbiota: a target for intervention in obesity
Kanika Sehgal, Sahil Khanna
Therapeutic Advances in Gastroenterology
|
March 22, 2021
Gut microbiome and <i>Clostridioides difficile</i> infection: a closer look at the microscopic interface
Kanika Sehgal, Sahil Khanna
Therapeutic Advances in Gastroenterology
|
May 17, 2021
Immune response against <i>Clostridioides difficile</i> and translation to therapy
Kanika Sehgal, Sahil Khanna
Intestinal Research
|
November 29, 2020
Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Translational Gastroenterology and Hepatology
|
November 29, 2023
The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent <i>Clostridiodes difficile</i>
Kanika Sehgal, Paul Feuerstadt
Alimentary Pharmacology & Therapeutics
|
September 2, 2024
Editorial: Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low-dose rivaroxaban or the combination: Secondary analysis of the COMPASS randomised controlled trial
Kanika Sehgal, Dennis L Shung
Therapeutic Advances in Gastroenterology
|
June 9, 2021
The interplay of <i>Clostridioides difficile</i> infection and inflammatory bowel disease
Kanika Sehgal, Devvrat Yadav, Sahil Khanna
JAMA
|
August 8, 2022
Treatment of Clostridioides difficile Infection
Kanika Sehgal, Adam S Cifu, Sahil Khanna
Infectious Disease Clinics of North America
|
August 12, 2025
Making Sense of Differing Guidelines for Clostridioides difficile Infection
Kanika Sehgal, Paul Feuerstadt, Mark H Wilcox
Page
of 2